BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target

Benzinga · 4d ago
BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.